Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

26 janv. 2021 10h35 HE | Source: Junshi Biosciences

New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percent

Trial met primary endpoint and key secondary endpoints with high statistical significanceResults from more than 1,000 high-risk patients were consistent with previous dataIn November, Lilly submitted...
24 janv. 2021 19h07 HE | Source: Junshi Biosciences

FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma

SHANGHAI, China, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and...
28 déc. 2020 20h22 HE | Source: Junshi Biosciences

Junshi Biosciences Announces Inclusion of Toripalimab in The China National Reimbursement Drug List

SHANGHAI, China, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and...
13 déc. 2020 19h00 HE | Source: Junshi Biosciences

CHOICE-01 Phase III Study of Toripalimab at the Interim Analysis Met Pre-Specified Primary Endpoint of Progression-Free Survival at the First-Line Treatment of Advanced NSCLC

SHANGHAI, China, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and...
01 déc. 2020 00h13 HE | Source: Junshi Biosciences

Junshi Biosciences Announces Dosing of First Patient in Phase I Study of Anti-TROP2 Antibody -TUB196 Conjugate

SHANGHAI, China, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and...
30 nov. 2020 18h55 HE | Source: Junshi Biosciences

Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006

SHANGHAI, China, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and...
07 oct. 2020 22h50 HE | Source: Junshi Biosciences

Combination Study with JS016 and LY-CoV555 for Patients with Mild-to-Moderate COVID-19 Symptoms Met Primary and Secondary Endpoints

-- Viral load, symptoms, and hospitalizations or ER visits reduced -- Request for EUA and BLA filings for the combination therapy anticipated in Nov 2020 and as early as 2Q2021, respectively-- Large...
28 sept. 2020 22h35 HE | Source: Junshi Biosciences

JUPITER-02 Phase III Global Study of Toripalimab at the Interim Analysis Met Pre-Specified Primary Endpoint of Progression-Free Survival in Recurrent or Metastatic Nasopharyngeal Carcinoma

SHANGHAI, China, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...
17 sept. 2020 18h00 HE | Source: Junshi Biosciences

Junshi Biosciences Receives Orphan Drug Designation from the U.S. FDA for Toripalimab for the Treatment of Soft Tissue Sarcoma

SHANGHAI, China, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...
16 sept. 2020 12h45 HE | Source: Junshi Biosciences

Junshi Biosciences and Wigen Biomedicine Enter Global Development and Commercialization Collaboration for Four Small Molecule Cancer Drug Candidates

SHANGHAI, China, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...

Page précédente

Page suivante